Skip to content
Accessibility help
Search NICE…
Skip to content
Menu
Sign in
Guidance
Standards and indicators
Clinical Knowledge Summaries (CKS)
British National Formulary (BNF)
British National Formulary for Children (BNFC)
Life sciences
More from NICE
Home
NICE guidance
In development
In development: Guidance, quality standards and advice
Skip to filters
Skip to results
Published
In consultation
In development
Awaiting development
Topic prioritisation
Filter (1 applied)
Skip to results
Keyword or reference number
Keyword or reference number
Apply filter
Expected publication date
Expected publication date
From date
To date
Apply date filters
Area of interest
Area of interest
COVID-19 (8)
Type
Type
Guidance (342)
Guidance programme
(
1 selected
)
Guidance programme
Clinical guidelines (27)
Diagnostics guidance (8)
Health technology evaluations (18)
HealthTech guidance (2)
Highly specialised technologies guidance (6)
Interventional procedures guidance (17)
Medical technologies guidance (10)
NICE guidelines (32)
Public health guidelines (1)
Technology appraisal guidance (342)
Apply filters
Showing 51 to 75 of 342
Sort by
Title
Date
Apply sorting
Guidance programme: Technology appraisal guidance
Remove Guidance programme: Technology appraisal guidance filter
Guidance, NICE advice and quality standards in development
Title
Type
Expected publication date
Brensocatib for treating non-cystic fibrosis bronchiectasis in people 12 years and over ID6448
Technology appraisal guidance
22 July 2026
Brexucabtagene autoleucel for treating relapsed or refractory mantle cell lymphoma after 2 or more systemic treatments (review of TA677) [ID6325]
Technology appraisal guidance
TBC
Burosumab for treating FGF23-related hypophosphataemia in tumour-induced osteomalacia [ID3924 ]
Technology appraisal guidance
TBC
Cabozantinib for treating advanced hepatocellular carcinoma after prior therapy [ID1243]
Technology appraisal guidance
24 May 2019
Cabozantinib for treating advanced neuroendocrine tumours that have progressed after systemic treatment [ID6474]
Technology appraisal guidance
TBC
Cabozantinib with nivolumab and ipilimumab for untreated intermediate- or poor-risk advanced renal cell carcinoma [ID6330]
Technology appraisal guidance
TBC
Camizestrant as an add-on to palbociclib and abemaciclib for untreated hormone receptor-positive HER2-negative metastatic breast cancer with an ESR1 mutation [ID6535]
Technology appraisal guidance
TBC
Canagliflozin for treating chronic kidney disease in people with type 2 diabetes [ID1653]
Technology appraisal guidance
TBC
Capivasertib with abiraterone for treating hormone-sensitive metastatic prostate cancer with PTEN deficiency [ID6466]
Technology appraisal guidance
TBC
Catumaxomab for intraperitoneal treatment of malignant ascites in epithelial cellular adhesion molecule-positive carcinomas when further systemic anticancer treatment is unsuitable [ID6580]
Technology appraisal guidance
30 September 2026
Cediranib with olaparib for treating recurrent platinum-resistant ovarian, fallopian tube or primary peritoneal cancer after 3 therapies [ID1639]
Technology appraisal guidance
TBC
Ciltacabtagene autoleucel for treating relapsed and lenalidomide-refractory multiple myeloma after 1 to 3 therapies [ID4012]
Technology appraisal guidance
TBC
Cimavax for treating wild-type EGFR-positive non-small-cell lung cancer [1259]
Technology appraisal guidance
TBC
Colon cancer (adjuvant) - irinotecan [ID379]
Technology appraisal guidance
TBC
Concizumab for treating haemophilia A or B in people 12 years and over with inhibitors [ID6665]
Technology appraisal guidance
TBC
Cositecan for treating platinum or taxane resistant advanced, mucinous, epithelial ovarian cancer [ID826]
Technology appraisal guidance
TBC
Daprodustat for treating anaemia in people with chronic kidney disease [ID3987]
Technology appraisal guidance
TBC
Daratumumab with bortezomib, lenalidomide and dexamethasone for untreated multiple myeloma when a stem cell transplant is unsuitable [ID3843]
Technology appraisal guidance
25 February 2026
Daratumumab with bortezomib, lenalidomide and dexamethasone for untreated multiple myeloma when an autologous stem cell transplant is suitable [ID6249]
Technology appraisal guidance
4 March 2026
Dasatinib for treating Philadelphia-chromosome-positive acute lymphoblastic leukaemia in children and adults ID1297
Technology appraisal guidance
TBC
Dasatinib for treating Philadelphia-chromosome-positive acute lymphoblastic leukaemia in children and adults ID1297
Technology appraisal guidance
28 July 2021
Datopotamab deruxtecan for previously treated hormone receptor-positive HER2-negative unresectable or metastatic breast cancer [ID6348]
Technology appraisal guidance
TBC
Datopotamab deruxtecan for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer [ID6435]
Technology appraisal guidance
TBC
Datopotamab deruxtecan for treating advanced non-small-cell lung cancer after platinum-based chemotherapy [ID6241]
Technology appraisal guidance
TBC
DCVax-L for treating glioblastoma [ID836]
Technology appraisal guidance
TBC
Previous page
1
2
Current page
3
4
5
…
14
Page
3
of
14
Next page
Results per page
10
25
50
All
Back to top